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Background: Little is known about the impact of COPD on lung deposition of inhaled drugs
and the relationship between lung-dose and response of pulmonary function measure-
ments.
Methods: Nineteen patients with varying degrees of COPD were randomized to inhale
single doses of formoterol (Oxiss) Turbuhalers 4.5, 9, 18, and 36 mg in a double blind,
placebo-controlled, crossover design. Urinary excreted formoterol during 32 h was used to
determine absolute lung deposition. Peak inspiratory flow (PIF) and inhaled volume (IV)
were recorded to assess the patients’ ability to use Turbuhaler. Efficacy was measured by
spirometry, inspiratory capacity (IC), airway conductance (sGAW), and absolute lung
volumes.
Results: Mean pulmonary bioavailability of formoterol was about 24% of the nominal
delivered dose after inhalation for the different treatments. No significant correlations
between lung deposition and baseline FEV1, PIF or IV were shown. All formoterol doses
produced statistically significant increases in FEV1, FVC, IC, and sGAW relative to placebo.
Linear dose/response relationships were observed for these variables, with more narrow
limits of the slopes for the lung-dose/response relationships than for the nominal-dose/
response relationships. Moreover, 36 and 18 mg formoterol statistically significantly
decreased functional residual capacity (FRC) and residual volume (RV) relative to placebo.
Conclusions: This study could not show any difference in lung deposition of formoterol
inhaled via Turbuhaler between patients with moderate and severe COPD. Moreover, theElsevier Ltd. All rights reserved.
nt from AstraZeneca, Lund, Sweden.
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E. Derom et al.1932effect of formoterol on various pulmonary function measurements were more closely
related to lung deposition than the inhaled nominal dose.
& 2007 Elsevier Ltd. All rights reserved.Figure 1 Double-blind, partly randomized, placebo controlled
crossover study with formoterol in patients with COPD. After
two screening visits, single doses of 4.5, 9, 18, and 36 mgIntroduction
Studies on lung deposition of inhaled bronchodilators
conducted in healthy subjects and in patients with asthma
have shown that the portion of the delivered drug deposited
in the airways is dependent on device characteristics and
inhalation technique.1 It has been repeatedly demonstrated
that this portion, the pulmonary bioavailability or lung
deposition of the drug, is responsible for the clinical effects
in asthma patients.2–4 According to current Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guidelines,
inhaled short- and long-acting bronchodilators are the
first choice in the medical treatment of patients with
moderate to severe chronic obstructive pulmonary disease
(COPD), since they improve symptoms, spirometric indices,
exacerbations, and quality of life.5,6 COPD patients are
characterized by airway obstruction, hyperinflation, mucus
hypersecretion, and pronounced disturbances in distribution
of ventilation,7 which is far more inhomogeneous than in
asthmatics.8 Therefore, uncertainty exists concerning the
penetration and deposition of inhaled drugs in the airways of
patients with COPD.
To the best of our knowledge, the deposition and fate of
inhaled drugs have not previously been systematically
investigated in COPD patients. If anything, discrepant data
have been reported in this area. Two studies showed that
pulmonary deposition of radioactive particles appeared to
be somewhat related to FEV1 in patients with COPD,
9,10
whereas another study was unable to demonstrate any
difference in total and regional lung deposition of inhaled
ipratropium bromide between healthy subjects and patients
with severe COPD.11
The present study was designed to assess inhalation
performance, lung deposition and efficacy of formoterol
(Oxiss), administered via a dry powder inhaler (Turbuha-
lers) in patients with COPD. The primary outcome was lung
deposition, determined as the absolute pulmonary bioavail-
ability of formoterol. Secondary objectives were the effects
of different inhaled formoterol doses on a variety of
pulmonary function variables, the relationship between
lung deposition and effect of formoterol on pulmonary
function, the potential influence of the degree of severity of
COPD on total lung deposition of formoterol, and the
patient’s ability to inhale via Turbuhaler.formoterol or placebo inhaled via Turbuhaler were given in
random order at each inhalation visit. The doses were given as
eight inhalations of 4.5 mg Oxis Turbuhaler or placebo via
Turbuhaler with one inhalation per inhaler and with inhalers
containing formoterol administered before placebo inhalers. In
between Visit 5 and 7, 10 mg of formoterol was given
intravenously (i.v.), to relate urine excretion of formoterol to
its systemic bioavalailability. Tel ¼ telephone call, AE ¼
adverse events.Patients, methods and study design
Patients
Patients were to be between 40 and 80 years of age, have a
clinical diagnosis of COPD with symptoms for at least 2 years
and be current or previous smokers with a smoking history ofat least 10 pack years. Only patients with stable COPD (i.e.
no significant exacerbation, defined as hospitalization, a
course of antibiotics or an increase in inhaled/oral corti-
costeroid dosage 2 months prior to entry into the study)
were to be included. They should exhibit a baseline FEV1 of
less than 80% predicted and at least 800mL, and a FEV1/FVC
ratio below 70%. Patients with a history of asthma or allergic
rhinitis and patients with COPD under long-term oxygen
therapy were to be excluded. Signed informed consents
were to be obtained. The study was performed in
accordance with the declaration of Helsinki and approved
by the Ethics Committee of Ghent University Hospital and
the National Board of Health and Welfare in Belgium. The
first patient was enrolled on 19 July 2001, the last subject
completed the study on 5 May 2003.Study design
The study was of placebo-controlled, double blind, double
dummy and had a partly randomized, six-period crossover
design. The study included eight visits and a telephone
contact for adverse events (Fig. 1). Eligibility was assessed
at Visit 1, and baseline pulmonary function measurements
were performed at Visit 2. Placebo and single doses of 4.5,
9, 18, and 36 mg formoterol Turbuhaler (dose strengths being
expressed as nominal delivered dose) were randomly
administered on five different study days (Visits 3–5, 7,
and 8) by inhalations of Oxiss Turbuhaler 4.5 mg and/or
lactose-containing placebo Turbuhaler. A single intravenous
dose of formoterol was given over 5min at Visit 6. The study
drug administrations were separated by a washout period of
at least 1 and no more than 3 weeks.
The inhalation technique was practiced using placebo at
Visit 2 and refreshed before inhaled drug administration at
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forcefully in standing position and were trained to reach a
peak inspiratory flow (PIF) of at least 60 L/min within 0.5 s.
Before use, Turbuhaler inhalers were primed by holding the
inhalers in an upright position and turning the grip three
times back and forth. The third dose was then inhaled.
Inhalations took place in a separate room. The patients and
clinical staff wore protecting gloves during inhalation to
avoid contamination of urine samples with formoterol. The
patients performed eight inhalations per visit, with one dose
of formoterol/placebo from each of the eight inhalers and
approximately 30 s in between. Formoterol was always
administered before placebo to minimize the potential
impact of the time factor between inhalations of formoterol
on pulmonary deposition.
PIF and inhaled volume (IV) generated during inhalation
through Turbuhaler were measured by connecting the
inhaler to a Vitalograph Compact I MDI spirometer (Vitalo-
graph Ltd., UK). Patients were instructed to breathe out
calmly, close their lips around the mouthpiece, and take one
forceful and deep breath. Thereafter, they put down the
inhaler, and breathed out through the nose. After inhalation
of the study drug, the patients washed their hands and
the outside of their mouth before leaving the drug
administration room. Two batches of formoterol Turbuhaler
were used, which had fine particles fractions (o5 mm) of 51%
and 54%.
In order to prevent oropharyngeal and gastrointestinal
absorption, activated charcoal was given orally as an
aqueous slurry (Carbomixs, Selena Fournier) at all study
visits as described before.12 The following protocol was
used: 5 g immediately before the start of inhalation or
infusion, 5 g immediately after inhalation or infusion, 10 g
1 h and 10 g 2 h after the start of inhalation or infusion. This
has been shown to completely block gastro-intestinal
absorption of orally administered formoterol (AstraZeneca,
data on file).
In the morning of Visit 6, 10 mg formoterol fumarate
dihydrate (2mL formoterol fumarate dihydrate solution for
injection, 5 mg/mL) was administered manually, over 5min,
at a constant rate via an indwelling catheter. The weight of
the syringes was recorded before and after infusion.
At Visits 3–8, urine was collected up to 32 h after
administration of the study drug for determination of
amount excreted formoterol.
Pulmonary function measurements were performed at
Visit 2 (baseline) and at Visits 3–5 and 7–8, before and 1.5 h
after inhalation of the study drug.Methods
Lung deposition
The total amount of formoterol excreted in urine, up to 32 h
after administration was used to determine lung deposition.
There is no evidence of local metabolism of formoterol in
the human lung and the orally administered charcoal
completely blocks the gastro-intestinal uptake of the
portion of formoterol deposited in the oropharynx. Thereby,
an estimate of systemic bioavailability, such as the dose-
corrected ratio of urine recovery after inhalation andintravenous administration, equals the lung deposition of
inhaled formoterol.
At Visits 3–8, patients were asked to empty their bladder
just before inhalation or infusion of the study drug and
aliquots of this urine were saved for baseline analysis.
Thereafter, urine was collected quantitatively in two
fractions, 0–6 and 6–32 h after administration of the study
drug. Aliquots from each urine fraction were stored at
20 1C until analysis.
The urine samples were analyzed at Quintiles AB,
Analytical Services, Uppsala, Sweden using a coupled
column LC-electrospray ionization (ESI)-MS/MS method with
a 2H4-labeled analog as internal standard to determine the
concentration of formoterol. The method was calibrated
over the concentration range 0.0400–50.0 nM with a lower
limit of quantification (LOQ) of 0.0400 nM.
One (1.00) mL urine, 100 mL internal standard (2H4-
labeled analog) solution and 0.1M ammonium acetate
buffer pH 5.0 were mixed. The samples were transferred
to conditioned solid phase extraction columns (Isolute
CBA, 200mg, 3mL) where the extraction was performed.
The eluates were evaporated to dryness. The residue
was dissolved in 250 mL 10% methanol and 0.5% acetic acid
in water. After mixing, the samples were centrifuged
and aliquots of the centrifuged samples were injected
onto the LC-ESI-MS/MS. The columns used in the coupled
column LC system were as follows: Column 1: Phenomenex
LUNA CN, 5 mM, 50 2.0mm; Column 2: Jones Chromato-
graphy Genesis C18 4 mm, 10 2.1mm; Column 3: Hichrome
ACE C18, 3 mm 50 2.1mm. Formoterol and the internal
standard were detected by using ESI positive ion
multipel reaction monitoring (MRM) of the transitions m/z:
345.00–149.20 (formoterol) and 349.00–153.30 (internal
standard). The mean accuracy values from the quality
control samples at 0.100, 10.0 and 40.0 nM were 104%, 100%
and 99%, respectively, and the corresponding precisions
were 4.6%, 1.8% and 2.9%, respectively. The lower limit of
quantification (LLOQ) was 40 pmol/L. The interassay
coefficient of variation was up to 4.6%. For urine concentra-
tions below the LLOQ, the concentration value was set to
zero.
For each portion of urine the amount of excreted
formoterol was calculated as formoterol concentration
times urine volume, corrected for urine density (1020 g/L).
The fraction of formoterol excreted in urine was
calculated as the quotient between the total amount of
formoterol excreted within 32 h and the administered
dose of formoterol. The nominal dose of formoterol
was used for inhaled treatments. The infusion volume
times the actual batch concentration was used for the
intravenous dose. Infusion volume was determined from the
difference in syringe weight before and after infusion,
corrected for the density of the solution (1.005 g/ml).
Furthermore, the intravenous dose was corrected for a
0.4% adsorption of formoterol in the infusion tube.
Lung deposition, determined as absolute pulmonary
bioavailability (Fpulm), was calculated as the dose-
corrected ratio of the total amount of formoterol ex-
creted over 32 h after inhaled and intravenous treat-
ments. The lung dose of formoterol after inhaled treatment
was calculated as the nominal dose times the lung
deposition.
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Pulmonary function measurements were performed accord-
ing to the ERS Guidelines.13 Efficacy was measured by means
of spirometry, inspiratory capacity (IC), functional residual
capacity (FRC), residual volume (RV), total lung capacity
(TLC), and specific airway conductance (sGAW), which have
all been used as a marker for bronchodilatation in
COPD.14–18 The same technician measured the parameters
at approximately the same time of the day.
Spirometry (FEV1 and FVC) was performed after a 15min
rest, using the pneumotachograph of a bodyplethysmograph
(Jaeger Masterlab, Wu¨rzburg, Germany). The highest FEV1
and FVC obtained from at least three acceptable forced
expiratory maneuvers were retained. Based on their FEV1,
patients were stratified into two groups with baseline FEV1
between 50% and 80% predicted and below 50% predicted.
Measurements of IC, FRC, RV, and TLC were performed,
using the helium dilution technique.19 Patients were in
sitting position and wore a nose clip. A constant volume
bodyplethysmograph (Jaeger Masterlab, Wu¨rzburg, Ger-
many) was used to measure airway resistance (RAW) and
sGAW.
A reversibility test was performed after spirometry at
Visit 1 by measuring FEV1 at 30min after four inhalations of
salbutamol 100 mg and four inhalations of ipratropium 40 mg
from pMDIs connected via a large volume spacer.
Restrictions
Smoking was not allowed from 1h before drug administra-
tion to 4 h after administration, nor were caffeinated
beverages from 8 h before drug administration to 4 h after
administration. Intake of food and liquids were not
permitted 1 h prior to and 4 h after administration of study
drug, except water, which was allowed after intake of
charcoal scheduled one hour after study drug administra-
tion. Patients were forbidden to do any strenuous physical
exercise within 2 h before administration of the study drug
to completion of the visit.
At least 30 days before Visit 1 and during the study period,
inhaled and oral corticosteroid therapy was kept constant
and administered at approximately the same time of the
day. Oral and inhaled long-acting ß2-agonists, tiotropium,
and theophylline were discontinued for at least 48 h prior to
all the visits, as were inhaled short-acting ß2-agonists,
inhaled ipratropium bromide for at least 8 h prior to all
visits. Leukotriene antagonists, b-blocking agents, including
eye drops, and any medication containing ephedrine were
not allowed during the study. Ipratropium bromide pMDI
40 mg/dose was to be used as rescue medication.
Statistical analysis
The statistical analysis was performed at AstraZeneca R&D
Lund using Gauss from Aptech Systems Inc. (Gauss Kernel
revision: 5.0.16) and the Rieman Library (version 2.0.0). All
data were used for analysis, regardless whether a patient
had quantifiable concentrations of formoterol in the predose
urine samples or not. All hypothesis testings were performed
using two-sided alternative hypotheses. P-values less than
5% were considered statistically significant.Absolute pulmonary bioavailability was estimated for the
different dose levels using a multiplicative analysis of
variance (ANOVA) model with patient, period, and treat-
ment as fixed factors. Dose proportionality regarding
pulmonary bioavailability was investigated by fitting a
straight line to the adjusted means (on the log scale) vs.
logged nominal dose using weighted linear regression.
The effect of inhaled formoterol on pulmonary function
efficacy variables (FEV1, FVC, IC, FRC, RV, TLC, and sGAW)
was compared between treatments using multiplicative
ANOVA models with patient, period and treatment as fixed
factors, and using baseline of the study as covariate. When
comparing active treatments with placebo, the highest dose
of formoterol was first compared with placebo and, if this
difference was statistically significant, then decreasing
doses of formoterol were compared until the placebo
difference was no longer statistically significant.
Nominal-dose/response relationships for FEV1, FVC, IC,
and sGAW were investigated by fitting straight lines to the
adjusted means (on the log scale) vs. logged nominal dose
using weighted linear regression. Relationships between
lung dose and the different pulmonary function variables
were expressed using mixed effect modeling. A linear mixed
effects model with random factor patient and with fixed
intercept and slope for the covariate (i.e. logged lung dose)
was used. Both models with effect measured on the log scale
(logged baseline ratios) and with effect measured on the
linear scale (baseline difference) were used.
Relationships between PIF and IV during inhalation via
Turbuhaler and baseline FEV1 were described graphically and
expressed by linear mixed effect models. Relationships
between lung deposition and PIF, IV, or baseline FEV1 were
described and expressed in the same manner.
Results
Patient characteristics
Nineteen (18 male) patients were included. Their demo-
graphic and baseline characteristics at Visit 1 are summar-
ized in Table 1. All patients were older than 40 years of age,
had a diagnosis of COPD, and had at least smoked 10 pack
years. None had the diagnosis of asthma. Of the 19
randomized patients, 11 had a baseline FEV1 between 50%
and 80% predicted and eight had a baseline FEV1 below 50%
predicted. The majority of the patients were hyperinflated
with a median FRC of 131% (range: 73–217%) predicted. Most
patients were on inhaled glucocorticosteroids at randomiza-
tion. There were no dropouts, other than patient No. 1, who
was withdrawn from the study after Visit 5, as he developed
a cerebrovascular accident. Some of his pulmonary function
data could be used, but absolute bioavailability could not be
assessed, since he never attended Visit 6.
Inhalation characteristics
PIF and IV via Turbuhaler were measured for each of the
eight inhalations at all study visits with inhaled treatments,
in total 744 inhalations. Mean PIF of all values was 59 L/min
(patient range: 45–73 L/min) and mean inhalation volume
was 2.20 L (patient range 1.39–3.42 L). PIF and IV were not
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remaining stable during the inhalation of the eight doses.
The variability in PIF and IV was higher between than within
patients. Mean IV increased statistically significantly with
increased baseline FEV1 (Fig. 2, slope value 0.017 with C.I.
between 0.009 and 0.025). Although mean PIF tended to be
slightly higher in patients with higher FEV1, the correlation
was not statistically significant (Fig. 2, slope value 0.130
with C.I. between 0.007 and 0.266), the mean difference
between patients with a FEV1 of 30% and a FEV1 of 70% beingTable 1 Demographic and lung function data.
Median
(minimum–maximum)
Age (years) 64 (44–81)
BMI (kg/m2) 25 (19–32)
Pack-years 30 (10–45)
FEV1 (L) 1.64 (0.95–2.43)
FEV1 (%) 54 (33–70)
FVC (L) 3.38 (1.83–4.73)
FVC (%) 82 (50–104)
FEV1/FVC (%) 51 (37–64)
Reversibility (% baseline) 16 (2–41)
Reversibility (% predicted) 8 (1–17)
FRC (% predicted) 131 (73–217)
RV (% predicted) 151 (83–241)
TLC (% predicted) 104 (75 –136)
sGAW (1 kPa
1 s1) 0.29 (0.11 –0.53)
Figure 2 PIF (upper left-hand pannel) and IV (upper right-hand pan
baseline FEV1. IV during inhalation of formoterol Turbuhaler, as a fuless than 6 L/min (Fig. 2). A higher PIF was statistically
significantly correlated with a higher IV (Fig. 2, slope value
0.024 with C.I. between 0.012 and 0.036).Lung deposition
All patients had formoterol concentrations above LLOQ in
the 0–6 h urine samples and 13 of the 18 patients had
concentration values above LLOQ in the 6–32 h urine
samples at all dose levels. The concentrations below LLOQ
in the 6–32 h urine samples were all found after adminis-
tration of the lowest dose, 4.5 mg. The mean fraction of
excreted unchanged formoterol in urine was 17.2% of the
10 mg intravenously administered dose. After inhalation of
4.5, 9, 18, and 36 mg formoterol, the fractional excretion of
unchanged formoterol in urine was 3.6%, 4.7%, 4.2%, and
3.9% of the nominal dose, respectively, giving mean
estimates of lung deposition ranging between 20.5% and
27.0% (Table 2). Mean lung deposition based on all four dose
levels was 24.0%. Dose proportionality in lung deposition ofnel) during inhalation of formoterol Turbuhaler, as a function of
nction of PIF (lower pannel).
Table 2 Absolute pulmonary bioavailability of formo-
terol (% of nominal dose).
Treatment Adjusted means Range
Formoterol 4.5 mg 20.5 4.8–100.7
Formoterol 9 mg 27.0 8.4–116.4
Formoterol 18 mg 24.4 11.1–41.2
Formoterol 36 mg 23.7 12.6–36.6
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lung and nominal dose was not statistically different from
zero (slope value 0.049% with 95% C.I. between 0.091 and
0.188).
A few high pulmonary bioavailability values were found
after inhalation of the two lowest doses (Fig. 3). Patient No.
3 had a lung deposition value of 76% after inhalation of 9 mg
formoterol and patients Nos. 13 and 18 had deposition
values of 101% and 116% after inhalation of 4.5 and 9 mg,
respectively. These three patients had formoterol above the
LLOQ in their baseline samples and an abnormally high
amount of formoterol excreted within 6–32 h, despite the
required temporary discontinuation of all formoterol treat-
ments before each study visit. Since the erroneous intake of
formoterol before and immediately after the study visits
could lead to an overestimation of the deposition data, a
sub-analysis was performed in those patients, that had no
detectable formoterol in their predose urine samples. This
yielded mean lung depositions of 17.6% (range: 8.4–34.2%),
23.0% (range: 11.1–41.2%), and 23.8% (range: 12.6–33.6%) of
the nominal dose for the 9, 18 and 36 mg dose, respectively,
and 12.4% (range: 5.1–39.5) for the 4.5 dose. In these
‘‘clean’’ patients, concentrations of formoterol were below
the LLOQ in the 6–32 h urine fraction in half of the patients
after inhalation of the 4.5 mg dose, explaining the low
deposition after 4.5 mg.
The influence of different covariates on lung deposition of
formoterol was investigated assuming dose-independent
lung deposition of formoterol. Linear mixed effects models
were fitted to the data. No statistically significant linear
correlations were observed between disease severity,
determined as baseline FEV1 at Visit 2 and lung deposition,
expressed as percentage of nominal dose (Fig. 3). MeanFigure 3 Lung deposition (determined as absolute pulmonary bi
function of baseline FEV1 (upper right-hand pannel), PIF (upper lefdeposition averaged 24.8% (95% C.I.: 21.7–28.3) of the
delivered dose for the patients with baseline FEV1 between
50% and 80% predicted and 23.3% (95% C.I.: 19.3–28.3) for
patients with baseline FEV1 below 50% predicted. Moreover,
no statistically significant linear correlation was observed
between lung deposition of formoterol and reversibility at
Visit 1, PIF or IV during the inhalation maneuver.Effects on pulmonary function
Changes in pulmonary function, measured before and 1.5 h
after inhalation of placebo and formoterol 4.5, 9, 18, and
36 mg are presented as geometric mean baseline ratios for
FEV1, FVC, IC and sGAW (Fig. 4). FEV1 increased by 8.4%
(0.14 L), 8.0% (0.14 L), 13.2% (0.22 L), and 18.6% (0.32 L)
from baseline after inhalation of 4.5, 9, 18, and, 36 mg
formoterol via Turbuhaler, respectively, whereas FEV1
remained stable (0.03 L) after placebo. Similar statistically
significant dose-dependent changes were observed for FVC,
IC, and sGAW. All formoterol doses induced statistically
significant increases in FEV1, FVC, IC, and sGAW, compared to
placebo. RV and FRC decreased statistically significantly at
the 18 and 36 mg formoterol dose compared to placebo.Relationship between nominal-dose and pulmonary
function variables
Dose/response relationships were investigated for FEV1,
FVC, IC, and sGAW (Fig. 4). Statistically significant correla-
tions between nominal dose and effect were observed for
FEV1, FVC, IC, and sGAW (Table 3), whether the changes wereoavailability, Fpulm) of formoterol inhaled via Turbuhaler as a
t-hand pannel) and IV (lower pannel).
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Figure 4 Change in pulmonary function variables, expressed as geometric mean baseline ratio, for the different treatments,
expressed as nominal dose. Statistically significant differences (defined as Po0.05) between all treatments (4.5, 9, 18 or 36 mg) and
placebo were observed for FEV1, FVC, IC and sGAW. Statistically significant nominal-dose/response relationships were observed for all
parameters.+ ¼ pulmonary function after placeobo;  ¼ pulmonary function after the active treatments.
Table 3 Estimated regression parameters of nominal-dose/response relationships and of lung-dose/response relationships of
lung function variables.
Variable Nominal-dose/response relationships Lung-dose/response relationships
Intercept Slope 95% C.I. Intercept Slope 95% C.I.
FEV1 0.002 0.045 0.016–0.075 0.07 0.041 0.019–0.063
FVC 0.010 0.035 0.012–0.058 0.04 0.029 0.015–0.044
IC 0.038 0.052 0.020–0.084 0.02 0.064 0.029–0.100
sGAW 0.216 0.082 0.008–0.157 0.35 0.072 0.009–0.136
Lung deposition and efficacy of formoterol 1937expressed as percentage from baseline or as absolute
change between pre and post dose.Relationship between lung-dose and pulmonary
function variables
Statistically significant correlations between lung-dose and
pulmonary function variables were found for FEV1, FVC, IC,
and sGAW (Fig. 5). Similar results were obtained, if absolute
changes in pulmonary function were used. The 95%
confidence intervals were more narrow for the lung-dose/
response relationships (Table 3) than for the nominal-dose/
response relationships, indicating that the effects on
pulmonary function were better described by lung deposi-
tion than by nominal dose.Adverse events
One patient was hospitalized between Visit 5 and 6, because
of stroke. This event, though serious, was not considered to
be related to the study drug. Similarly, another patient was
hospitalized for a cholelithiasis.
Discussion
Lung deposition
The present study showed that about 24% of formoterol
delivered via Turbuhaler is deposited in the lungs of patients
with moderate and severe COPD. In addition, the effects on
pulmonary function were related to both the nominal dose
ARTICLE IN PRESS
Figure 5 Change in pulmonary function variables, expressed as % change from baseline, for the different treatments, expressed as
lung-dose. Statistically significant dose/response relationships were observed for FEV1, FVC, IC and sGAW.
E. Derom et al.1938of formoterol and the amount deposited in the lung, with a
closer relationship to the latter. This suggests that lung
deposition may be used as a surrogate marker for the clinical
effects of inhaled formoterol in COPD, in line with what has
previously been shown for a number of drugs in patients with
asthma.1 A pertinent finding is that no correlation between
baseline FEV1 and lung deposition was observed.
The reliability of urinary data is important in determining
the accuracy of the lung deposition and the validity of the
correlations between lung deposition and pulmonary func-
tion variables. Factors that could have interfered with the
accuracy of the lung deposition data were: incompleteness
of the urine collections, mistakes in discontinuation of
formoterol therapy by the patients immediately before and
after the study days, and inability to detect urinary
concentrations of formoterol below the LLOQ.
In order to ensure completeness of the urine collections,
patients remained under close supervision at the clinic for
the first 6 h after study drug administration—(a time
interval during which 60–70% of the formoterol is expected
to be excreted). Of the 108 urine collections performed
outside the hospital, only one (placebo) was documented to
be incomplete.
Three patients showed extremely high lung deposition
values on one occasion each. Only not permitted use of
formoterol might explain these values. Two of these patients
were on regular treatment with formoterol before entering
the study, and apparently did not interrupt their treatment
in time or resumed the inhalation of formoterol too early,
i.e. before completion of the 6–32 h urine collection. This is
supported by the analysis of the urine, obtained pre-dose atVisits 3–8, which contained formoterol. However, the impact
of this overestimation of individual lung deposition on mean
lung deposition appeared to be of limited importance. A sub
analysis of the patients in whom no formoterol could be
detected in the pre-dose urine did not invalidate our
conclusions, since lung deposition values of formoterol
Turbuhaler in these patients ranged between 18% and 24%
of the delivered dose, at least for the three highest doses.
This was approximately the same mean value seen in the
group as a total. The mean lung deposition was lower, 12%,
at 4.5 mg in these patients. This is most probably due to
urine concentration values below the LLOQ and thereby an
underestimation of lung deposition.
The mean lung deposition of formoterol inhaled via
Turbuhaler by the COPD patients in the present study was
24% of the nominal dose, with a 95% C.I. between 21% and
26%. This value is close to the value obtained in a study of
healthy subjects and asthmatic patients (1) and in healthy
subjects with formoterol Turbuhaler, 28% (range: 17–45%),
but lower than the 49% (39–63%) reported in another study
with formoterol Turbuhaler, again in healthy subjects.20 The
present value is, however, higher than the corresponding
values in asthmatic patients from two previous studies on
terbutaline Turbuhaler performed with the same methodol-
ogy in the same clinic.3,4
Some physicians have argued that patients might not be
able to produce a high enough PIF through a DPI, such as
Turbuhaler, to generate an aerosol containing a sufficient
amount of fine particles in situations perceived as con-
strained.21 Actual data do not support this preconceived
notion.22 Even so, a large majority of COPD patients were
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40 L/min during an exacerbation despite overt respiratory
muscle weakness.23 In the present study, mean PIF was 59 L/
min, while the lowest mean individual PIF was 45 L/min.
Interestingly, the patient with the lowest PIF had a lung
deposition, close to the mean deposition value. Thus, the
present lung deposition value largely exceeded the 11.7%
lung deposition of ipratropium bromide inhaled via a
standard pMDI, in COPD patients.11
The analysis of the more than 700 inhalations in the
present study indicate that stable COPD patients with a
baseline FEV1 between 30% and 50% predicted are able to
produce a PIF through Turbuhaler vastly exceeding 30 L/min.
It should also be noted that there was no correlation
between PIF and disease severity measured as baseline FEV1
nor pulmonary deposition. This indicates that a satisfactory
pulmonary deposition might be expected also with a PIF
below 60 L/min, a flow that was once proposed to be the
target flow with Turbuhaler.24,25 Hence, the concerns about
the lack of efficacy of treatments with drugs inhaled via
Turbuhaler in COPD patients unable to reach an inhalation
flow rate of 60 L/min,21,26 are not supported by present lung
deposition data.
The current data also indicate that a reduced IV did not
compromise lung deposition of formoterol in COPD patients.
Actually, patients with a FEV1 as low as 0.950 L (or 33% of
predicted) or a FVC as low as 1.83 L (or 50% of predicted)
were included in the study. Although patients with a greater
FEV1 or PIF generated a greater IV, when inhaling via
Turbuhaler, there was no correlation between baseline FEV1
and lung deposition. If anything, a trend towards a better
response in FEV1 and FVC for severe, as compared to
moderate, COPD patients was observed.Pulmonary effects
The present study demonstrated that formoterol inhaled via
Turbuhaler resulted in a dose-dependent increase in mean
FEV1 reaching 19% of baseline with the highest, 36 mg, dose.
Likewise, mean sGAW increased by 67% with the highest
dose. These improvements are in line with other studies
with COPD patients, in which dose-dependent effects of
formoterol on FEV1 and airway resistance have been
reported.27–29
Measurements of FVC or IC reflect the degree of
hyperinflation, which appear to be far more responsive to
inhalation of short- and long-acting bronchodilating drugs
than FEV1.
17,18,30–38 Reduction of flow limitation and
hyperinflation has been considered to be one of the main
mechanisms through which short- and long-acting broncho-
dilating drugs improve exertional dyspnea and endurance in
COPD.39–43 The presently reported reduction in hyperinfla-
tion after formoterol was dose dependent, the 36 mg dose
resulting in the most pronounced decrease. This finding
provides a likely physiological explanation for the previously
reported reduction of dyspnea for the 4.5, 9 and 18 mg
doses44 and increase in exercise tolerance for the 4.5 and
9 mg doses.45 Whether a dose of 36 mg may further enhance
long-term exercise tolerance or reduce sensation of dyspnea
is not unlikely, since both our study and that of Cazzola et al.
unequivocally demonstrated that the effects on pulmonaryfunction of 36 mg formoterol inhaled via Turbuhaler ex-
ceeded those of the 18 mg dose.27 It thus appears that the
‘‘maximum’’ and the ‘‘optimal’’ dose might exceed the
currently recommended dose of 18 mg for maintenance
treatment of COPD. Apparently, the 36 mg dose was very
well tolerated as a single dose in the present study, as were
doses up to 90 mg of inhaled formoterol in another series of
patients with COPD.46
We did not only make estimations of regression para-
meters of nominal-dose/response relationships, but also of
lung-dose/response relationships, hypothesizing that lung-
dose could be used as a sharper surrogate marker for the
effects of inhaled formoterol in COPD. In fact, lung-dose was
a better predictor of functional improvement than nominal-
dose for FEV1, FVC, IC, and sGAW, since the confidence
intervals were tighter for the lung-dose/relationship than
for the nominal-dose/response relationship. The present
investigations thus indicate that lung deposition is of clinical
relevance in COPD, just as in asthma.2Conclusion
It can be concluded that moderate as well as severe COPD
patients manage to inhale formoterol properly via Turbu-
haler. In the 4.5–36 mg dose range, lung deposition is about
24% both in moderate and severe COPD, and results in a
dose–response for fev1, FVC, IC, and sGAW. More importantly,
a sharper dose–response relationship could be shown
between lung-dose of inhaled formoterol and effects on
pulmonary function. This study suggests that lung deposition
could serve as a surrogate for clinical effects and assessment
of bioequivalence of different formulations containing the
same bronchodilating drug.Conflict of interest
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